Trial Profile
The effects of fingolimod on the cardiovascular autonomic nervous system in patients with highly active relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 May 2014
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 13 May 2014 New trial record
- 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.